Phase I study of dasatinib plus erlotinib in recurrent malignant glioma
Latest Information Update: 17 May 2021
Price :
$35 *
At a glance
- Drugs Dasatinib (Primary) ; Erlotinib (Primary)
- Indications Glioma
- Focus Adverse reactions
- 26 Apr 2012 Actual patient number (47) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.